We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Researchers Characterize PrimPol, a Novel Human DNA Polymerase

By LabMedica International staff writers
Posted on 19 Nov 2013
PrimPol, a novel enzyme cloned in human cells, has been shown to initiate DNA chains with deoxynucleotides unlike regular primases, which exclusively use ribonucleotides.

Investigators at the biotechnology company SYGNIS AG (Madrid, Spain; and Heidelberg, Germany) in collaboration with researchers at the Spanish National Research Council (Madrid) recently isolated and characterized PrimPol.

They reported in the October 24, 2013, online edition of the journal Molecular Cell that PrimPol functioned as both DNA primase and DNA polymerase, and demonstrated high tolerance to damaged DNA. More...
The primase function of PrimPol allowed it to begin reading and copying DNA without the need for random ribonucleotide primers, as required by all other commercially available polymerases. The use of random primers can bias sequencing and amplification results. The polymerase function of PrimPol displayed high specific activity, being extremely efficient when copying DNA strands with different lesions, such as abasic sites or 8-oxoguanine.

Subcellular fractionation and immunodetection studies showed that PrimPol could be found in both nuclear and mitochondrial DNA compartments. Its activity was detectable in mitochondrial lysates from human and mouse cells but was absent from mitochondria derived from mice that had been genetically engineered to lack the PRIMPOL gene. PRIMPOL gene silencing or ablation in human and mouse cells impaired mitochondrial DNA replication.

Senior author Dr. Luis Blanco, research professor at the Spanish National Research Council, said, "I am convinced that this fantastic enzyme will open numerous novel applications in the field of molecular biology, some of them we can only hint at this moment given the highly innovative potential of its key features."

SYGNIS AG is currently developing a new thermostable version of the enzyme that is expected to make an important contribution to the DNA amplification and sequencing field.

Related Links:

SYGNIS AG 
Spanish National Research Council



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.